EXPERIENCES WITH PRICE COMPETITION OF BIOSIMILAR DRUGS IN HUNGARY

被引:0
|
作者
Hornyak, L. [1 ]
Nagy, Z. [2 ]
Talos, Z. [1 ]
Agoston, I [2 ]
Endrei, D. [2 ]
Csakvari, T. [3 ]
Boncz, I [4 ]
机构
[1] Csolnoky Ferenc Hosp, Veszprem, Hungary
[2] Univ Pecs, Pecs, Hungary
[3] Univ Pecs, Zalaegerszeg, Hungary
[4] Univ Pecs, Fac Hlth Sci, Pecs, Hungary
关键词
D O I
10.1016/j.jval.2014.08.1018
中图分类号
F [经济];
学科分类号
02 ;
摘要
PHP83
引用
收藏
页码:A418 / A418
页数:1
相关论文
共 50 条
  • [21] Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018
    Rome, Benjamin N.
    Lee, ChangWon C.
    Kesselheim, Aaron S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) : 367 - 371
  • [22] MarketWatch - Authorized generic drugs, price competition, and consumers' welfare
    Berndt, Ernst R.
    Mortimer, Richard
    Bhattacharjya, Ashoke
    Parece, Andrew
    Tuttle, Edward
    HEALTH AFFAIRS, 2007, 26 (03) : 790 - 799
  • [23] A boost for biosimilar drugs
    Hess, Glenn
    CHEMICAL & ENGINEERING NEWS, 2017, 95 (25) : 16 - 16
  • [24] Difficulties with biosimilar drugs
    Rice, M
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (15) : 2203 - 2203
  • [25] Biosimilar drugs in oncology
    Leveque, Dominique
    BULLETIN DU CANCER, 2016, 103 (03) : 294 - 298
  • [26] BIOSIMILAR DRUGS ARE NOT GENERICS
    Zangeneh, Farhad
    Dolinar, Richard
    ENDOCRINE PRACTICE, 2016, 22 (01) : 6 - 7
  • [27] Biosimilar competition: Early learning
    Frank, Richard G.
    Shahzad, Mahnum
    Kesselheim, Aaron S.
    Feldman, William
    HEALTH ECONOMICS, 2022, 31 (04) : 647 - 663
  • [28] Competition and Biosimilar Products Reply
    Chandra, Amitabh
    Vanderpuye-Orgle, Jacqueline
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (24): : 2692 - 2692
  • [29] Generic Price Competition For Specialty Drugs: Too Little, Too Late?
    Cole, Ashley L.
    Dusetzina, Stacle B.
    HEALTH AFFAIRS, 2018, 37 (05) : 738 - 742
  • [30] PRICE REFORM IN HUNGARY
    HORCHLER, G
    REVUE DE L EST, 1974, 5 (01): : 125 - 152